Modality Independence

Arcus is pursuing its therapeutic portfolio in a modality-independent fashion

We have selected some biological pathways that are best suited to modulation by small-molecule drugs (which are being designed entirely by our internal drug discovery team). Other biological targets in our drug discovery portfolio will be best addressed with protein-based therapeutics (which will be created in collaboration with external expert organizations). Both types of drug candidates will converge into the biological / preclinical / clinical development organization that we are presently building within Arcus.